| Bioactivity | WNT7A-IN-1 (1365-0109), a WNT7A inhibitor, disrupts the protein–protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 (1365-0109) significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin[1]. |
| CAS | 29133-39-9 |
| Formula | C37H36N2O8S2 |
| Molar Mass | 700.82 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jiazheng Sun, et al. Blocking WNT7A Enhances MHC-I Antigen Presentation and Enhances the Effectiveness of Immune Checkpoint Blockade Therapy. Cancer Immunol Res. 2024 Nov 27. |
WNT7A-IN-1
CAS: 29133-39-9 F: C37H36N2O8S2 W: 700.82
WNT7A-IN-1 (1365-0109), a WNT7A inhibitor, disrupts the protein–protein interaction between WNT7A and its receptor FZD5
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.